神经退行性疾病中的抑郁:神经生物学机制与新兴治疗
本文为叙述性综述,聚焦阿尔茨海默病(AD)与帕金森病(PD)中抑郁的神经生物学机制及新兴治疗。文中指出抑郁综合征影响超过三分之一患者,现有抗抑郁药疗效甚微,并汇总了靶向谷氨酸、血清素、多巴胺、免疫及环路功能的新型药物与神经调控干预。
要点
- AD和PD中抑郁综合征影响超过三分之一患者,与认知下降加速和生活质量降低相关。
- 现有抗抑郁治疗在该人群疗效甚微,提示神经退行背景下抑郁机制可能不同。
- 谷氨酸调节剂、多巴胺能药、κ阿片拮抗剂、免疫调节及新一代脑刺激是潜在方向。
核心结论
- 神经退行性疾病中的抑郁可能反映疾病特异性神经生物学机制,是机制导向抗抑郁药开发的独特模型。
研究设计与样本
- 叙述性综述,综合分子影像、神经病理学与认知神经科学证据,评估AD和PD中抑郁的机制与新兴治疗。
主要发现
- AD和PD中抑郁综合征影响超过三分之一患者,并与认知下降加速、生活质量降低和医疗使用增加相关。
- AD和PD存在疾病特异性的单胺能、谷氨酸能、炎症及奖赏相关环路紊乱,可能削弱标准抗抑郁药作用并导致治疗抵抗。
- 认知障碍患者常被排除在抗抑郁试验之外,评估新型疗法的高质量研究很少。
关键数值与推荐
- AD和PD中抑郁综合征影响超过三分之一患者。
- 当前抗抑郁治疗在该人群显示很小或无疗效。
- 新兴干预包括谷氨酸调节剂、多巴胺能药物、κ阿片拮抗剂、免疫调节疗法及下一代脑刺激。
临床怎么用
- 临床应认识AD和PD中抑郁的高负担及标准抗抑郁药疗效有限。
- 治疗开发宜与疾病特异性环路和分子病理对齐,关注谷氨酸、多巴胺、免疫及环路靶点。
局限性
- 为叙述性综述,非系统评价。
- 认知障碍患者常被排除在抗抑郁试验外,针对该人群的高质量研究很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Depression is one of the most common and disabling neuropsychiatric complications of neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD), depressive syndromes affect more than one-third of patients and are associated with accelerated cognitive decline, reduced quality of life, and increased healthcare utilisation. Despite this burden, current antidepressant treatments show little or no efficacy in these populations, suggesting that depression arising in the context of neurodegeneration may reflect distinct underlying neurobiological mechanisms. Emerging evidence from molecular imaging, neuropathology, and cognitive neuroscience indicates disease-specific disruption of monoaminergic, glutamatergic, inflammatory, and reward-related circuits in AD and PD. These alterations may undermine the mechanisms of action of standard antidepressants and contribute to treatment resistance. Yet patients with cognitive impairment are routinely excluded from antidepressant trials, and few high-quality studies have evaluated novel therapies in neurodegenerative disease. In this narrative review, we synthesise current evidence on the neurobiological mechanisms underpinning depression in AD and PD and critically evaluate emerging pharmacological and neuromodulatory therapies targeting glutamatergic, serotonergic, dopaminergic, immune, and circuit-level dysfunction. Here, we highlight that depression in neurodegenerative disease offers a unique and underutilised model for mechanistically guided antidepressant development. We identify how interventions including glutamate modulators, dopaminergic agents, kappa opioid antagonists, immune-modulating therapies, and next-generation brain stimulation approaches may offer therapeutic promise. By aligning treatment development with disease-specific circuit and molecular pathology, this framework may improve outcomes for this neglected population while advancing precision psychiatry more broadly.
引用
- Costello H, Reeves S, Glue P, et al. Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments. Mol Psychiatry. 2026. PMID: 42410083. doi:10.1038/s41380-026-03728-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。